# MARKET_RESEARCH_LOG_2026-08-27

> Production GenGe V3.1.1 hourly scan handoff. Repository `main` remains the source of truth. This log records completed production artifacts and is not an automatic trading instruction.

## 2026-08-27 00:10 CST — hourly opportunity + holdings risk refresh

- Production contract re-read from current main: `GEN_GE_V3_1_1_PRODUCTION`; LOW/INVALID valuation confidence -> HOLD_REVIEW; Hard Gate FAIL -> EXIT; no V3.2 sell-confirmation rules imported.
- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- `603658 安图生物`: RESEEN / NO MATERIAL CHANGE; WAIT; Formal BUY NO. Existing H1 earnings/cash-flow deterioration, slower demand/pricing-pressure evidence, incomplete moat audit and incomplete Bear/Base/Bull reverse valuation remain controlling. Exact accepted execution-grade close remained 34.17 CNY on 2026-08-25.
- Holdings: 今世缘 HOLD_REVIEW / NO ADD; 润贝航科 HOLD_REVIEW; 恒瑞医药 HOLD_REVIEW; 国电南瑞 HOLD_REVIEW. New REDUCE/EXIT: NONE. New thesis invalidation: NONE.
- Production/CI refresh found no confirmed chain failure. Notification threshold not met.

## 2026-08-27 01:08 CST — hourly opportunity + holdings-risk refresh

- Re-read repository truth sources and rebuilt holdings only from `CURRENT_HOLDINGS.md`.
- `603658 安图生物`: RESEEN / NO MATERIAL CHANGE; WAIT; Formal BUY NO; valuation confidence INVALID. Existing blockers unchanged; no new execution-eligible A1/A2.
- `001316 润贝航科`: exact 2026-08-26 close resolved to 26.69 CNY; this is `PRICE_ONLY_CHANGE / PRICE_FRESHNESS_RESOLVED`, not a rating/action change. Insider/shareholder reduction plan remains a governance/supply-overhang watch; strong 2026H1 operating growth still prevents REDUCE/EXIT.
- `603369 今世缘`: HOLD_REVIEW / NO ADD; accepted 2026-08-26 close 28.10 CNY.
- `600276 恒瑞医药`: HOLD_REVIEW; accepted 2026-08-26 close 46.74 CNY.
- `600406 国电南瑞`: HOLD_REVIEW; accepted 2026-08-26 close 23.42 CNY; H1 cash-conversion/margin deterioration remains under review.
- New REDUCE/EXIT: NONE. New hard-thesis invalidation: NONE. Notification threshold not met.

## 2026-08-27 02:05 CST — hourly opportunity + holdings-risk refresh

### Data cutoff / reproducibility

- Re-read current `main` truth sources before decisioning, including `AGENTS.md`, the production V3.1.1 contract reflected in current logs/handoff, `CURRENT_MARKET_RESEARCH.md`, `RESEARCH_QUEUE.md`, `MODEL_EVOLUTION_LOG.md`, `V31_CANDIDATE_LEDGER.md`, `CURRENT_HOLDINGS.md`, and `V31_DURABLE_HANDOFF.md`.
- Latest completed A-share trading session remains 2026-08-26; no new trading session occurred after the previous hourly refresh.
- Holdings universe rebuilt exclusively from `CURRENT_HOLDINGS.md`: `603369 今世缘`, `001316 润贝航科`, `600276 恒瑞医药`, `600406 国电南瑞`.
- Public post-close filing/event refresh cutoff: 2026-08-27 02:05 CST. Fresh-data invariant remains mandatory; stale/unverified price cannot create Formal BUY/ADD or a price-dependent REDUCE.

### Opportunity / ledger delta

- `603658 安图生物`: **RESEEN / NO MATERIAL CHANGE**. Tier `WAIT`; Formal BUY `NO`; production action `HOLD_REVIEW`; valuation confidence remains INVALID.
- No new post-01:08 filing/event evidence changes the controlling thesis: company-confirmed slower IVD demand growth, homogeneous competition and procurement-price pressure; 2026H1 profit/cash-flow deterioration; unresolved moat strength under that regime; incomplete normalized earnings and Bear/Base/Bull reverse valuation.
- Exact accepted execution-grade close remains **34.17 CNY on 2026-08-25**. Public evidence for 2026-08-26 still does not establish the second independently accepted exact 15:00 close required by the production freshness rule. Observed entry band remains **33.58–34.15 CNY** but cannot override fundamental/confidence blockers.
- Ledger persisted with `last_seen=2026-08-27 02:05 CST`, `seen_count=17`, run_id `hourly-20260827-0205`.
- No NEW / UPGRADED / DOWNGRADED / INVALIDATED execution-eligible candidate; no new A1/A2; no Formal BUY/ADD.

### Holdings risk delta

- `603369 今世缘`: **HOLD_REVIEW / NO ADD**. Accepted 2026-08-26 close 28.10 CNY. Structural baijiu demand/channel pressure remains the burden of proof; no new post-close filing/event establishes a fresh REDUCE/EXIT trigger.
- `001316 润贝航科`: **HOLD_REVIEW**, not REDUCE. Accepted 2026-08-26 close 26.69 CNY. The management/shareholder reduction plan remains a governance/supply-overhang watch, but 2026H1 revenue/profit/cash-flow growth remains strong and no new evidence links the plan to order, margin, cash-conversion or management-continuity deterioration.
- `600276 恒瑞医药`: **HOLD_REVIEW**. Accepted 2026-08-26 close 46.74 CNY. No new post-01:08 pipeline, governance, customer or moat evidence creates REDUCE/EXIT.
- `600406 国电南瑞`: **HOLD_REVIEW**. Accepted 2026-08-26 close 23.42 CNY. H1 cash-conversion and margin deterioration remain the active review issue; no new order/moat evidence escalates to REDUCE/EXIT.
- **New REDUCE/EXIT:** NONE. **New hard-thesis invalidation:** NONE.

### Production / data-source health

- Public post-close refresh returned no evidence of a production-chain or data-source failure that would invalidate the scan. Fresh-data fail-closed behavior remains active for unresolved exact-price evidence.
- No model threshold, valuation rule, holdings universe, or production policy was changed in this run.

### Notification decision

- **NO USER NOTIFICATION.** No new A1/A2 entered an executable buy range; no important new name entered `CURRENT DEEP RESEARCH QUEUE`; no material candidate rating/valuation/entry-band change; no holding REDUCE/EXIT or hard-thesis invalidation; no confirmed production/data/CI failure making the scan unreliable.
